Helping you detect, treat and manage arthritis

Reminder: Call for patient input on tofacitinib (Xeljanz®) for psoriatic arthritis

Megaphone GraphicDo you have psoriatic arthritis or care for someone who does? We need your valuable input.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input on the manufacturer’s submission for tofacitinib (Xeljanz®) for the treatment of psoriatic arthritis (PsA) when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient groups, like Arthritis Consumer Experts (ACE). We would like to gather your views and share them with the CDR.

These are the questions they are asking:

  1. What are the psoriatic arthritis related symptoms and problems that impact the patients’ day-to-day life and quality of life? For example: what aspects of psoriatic arthritis are more important to control, how does psoriatic arthritis affect day-to-day life, and are there any activities that the patient is not able to do as a result of psoriatic arthritis?
  2. How well are patients managing their psoriatic arthritis with currently available treatments? Examples of the types of information to be included in the answer are:
    • What therapy are patients using for psoriatic arthritis?
    • How effective is current therapy in controlling the common aspects of psoriatic arthritis?
    • Are there adverse effects that are more difficult to tolerate than others?
    • Are there hardships in accessing current therapy?
    • Are there hardships in receiving the treatment (swallowing pills, infusion lines)?
    • Are there needs, experienced by some or many patients, which are not being met by current therapy?
    • What are these needs?
  3. What challenges do caregivers face in caring for patients with psoriatic arthritis?
    • How do treatments impact on the caregivers’ daily routine or lifestyle?
    • Are there challenges in dealing with adverse effects related to current therapy?
  4. Based on no experience with tofacitinib for the treatment of psoriatic arthritis, what are the expectations for the medication?
    • Is it expected that the lives of patients will be improved by tofacitinib, and how?
    • Is there a particular gap or unmet patient need in current therapy that tofacitinib will help alleviate?
    • Would patients be willing to experience serious adverse effects with tofacitinib if they experienced other benefits from the medication?
    • How much improvement in the condition would be considered adequate? What other benefits might tofacitinib have, for example, fewer hospital visits or less time off work?
  5. What experiences have patients had to date with tofacitinib as part of a clinical trial or through a manufacturer’s compassionate supply?
    • What positive and negative effects does tofacitinib have on the condition?
    • Which symptoms does tofacitinib manage better than the existing therapy and which ones does it manage less effectively?
    • Does tofacitinib cause adverse effects?
    • Which adverse effects are acceptable and which ones are not?
    • Is tofacitinib easier to use?
    • How is tofacitinib expected to change a patient’s long-term health and wellbeing?

If you live with psoriatic arthritis or care for someone with the disease, please send us your input by Friday, July 27, 2018, so that we may submit a report by the August 1st deadline. Your input will be anonymous.

Please contact us at info@jointhealth.org to provide your input or arrange for a phone interview at 604-974-1366.